R Squared’s CRISPR Therapeutics CRSP Stock Holding History

R Squared’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,770	Closed	-$329K	–	587
2025 Q2	$329K	Buy	+6,770	New	+$262K	0.18%	198

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

R Squared's CRSP Position: Q3 2025 in Review

R Squared sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 6,770 shares — an estimated $329K sold.

R Squared first reported a position in CRSP in Q2 2025 and held it in 1 quarter. The position peaked at $329K in Q2 2025. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

R Squared reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
R Squared sold 6,770 CRISPR Therapeutics shares in Q3 2025, an estimated $329K.
R Squared first reported a position in CRISPR Therapeutics in Q2 2025 and held it in 1 quarter.
R Squared's CRISPR Therapeutics position peaked at $329K in Q2 2025.
440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on R Squared's 13F filing for Q3 2025, filed 12 Nov 2025.